MENY
Administratör Logga ut

BGB-3111-304

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

BGB-3111-304
An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PLACEHOLDER
Randomisering mellan Rituximab + Bendamystin eller BGB
Mer information om studien för vårdgivare
confirmed diagnosis of CD20-positive CLL or SLL, requiring treatment as defined by at least one of the following: progressive marrow failure; massive, progressive or symptomatic splenomegaly; massive, progressive or symptomatic lymphadenopath.>65 år
Behandling
Fas 3
Palliativ
Företag

Studien ändrades senast av: studyjohanna (2019-04-22)

Tillbaka till listan

Sidan uppdaterad: 25 september 2018